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ABSTRACT
CLOSTRIDIOIDES DIFFICILE BIOFILM AND SPORE PRODUCTION IN RESPONSE TO
ANTIBIOTICS AND IMMUNE STRESS
Adenrele M. Oludiran
Old Dominion University, 2022
Director: Dr. Erin B. Purcell

The development of new therapeutic options against Clostridioides difficile (C. difficile)
infection is a critical public health concern, as the causative bacterium is highly resistant to
multiple classes of antibiotics. C. difficile, an anaerobic spore-forming Gram-positive pathogenic
bacterium, is a major cause of hospital-acquired infections. C. difficile persists in the
environment and spreads the infection to new hosts in the form of dormant spores and can persist
within hosts as surface-attached biofilms. These studies investigate bacterial vegetative cell
survival, biofilm formation, and sporulation in response to stress. Antimicrobial host-defense
peptides (HDPs) are highly effective at simultaneously modulating immune system function and
directly killing bacteria through membrane disruption and oxidative damage. HDPs produced
naturally by animal immune systems are promising candidates to develop novel therapies for
bacterial infection because they cause oxidative stress that damages multiple targets in bacterial
cells, so it is difficult for bacteria to evolve resistance to these attacks. We investigate the C.
difficile response to HDPs applied alone or in combination with antibiotics and to oxidative
stresses similar to those caused by the human immune system. In our investigation of fishderived copper-binding HDPs known as piscidins applied to C. difficile in an anaerobic
environment, we found that the interaction of piscidin and copper depends on environmental
oxygen. While copper-binding increases piscidin potency in an aerobic environment, copper

does not synergize with these peptides anaerobically. Piscidins suppress the proliferation of C.
difficile by killing bacterial cells and strongly increase the efficacy of multiple classes of
antibiotics when applied in combination. Piscidins disrupt the bacterial cell membrane and
increase the uptake of exogenous substances. We find that piscidins are effective against
epidemic C. difficile strains that are highly resistant to other stresses. While extracellular stress
can induce C. difficile to sporulate or form biofilm for protection, piscidins alone kill vegetative
C. difficile cells without triggering spore formation and repress antibiotic-induced sporulation
after combined treatments. Piscidins may stimulate more C. difficile biofilm formation at subinhibitory doses, so dosage will need to be carefully considered in any potential infection
treatments using these peptides.
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NOMENCLATURE

CDI

Clostridioides difficile infection

FMT

Fecal microbiota transplantation

FDA

Food and Drug Administration

ROS

Reactive oxygen species

RNS

Reactive nitrogen species

°C

Degrees Celsius

BHIS

Brain heart infusion supplemented

TY

Tryptone yeast

LB

Luria-Bertani

×g

Times gravity

DNA

Deoxyribonucleotide

PBS

Phosphate buffered saline

DIC

Differential interface contrast

PI

Propidium iodide

CFU

Colony forming unit

ECM

Extracellular matrix

VAN

Vancomycin

MET

Metronidazole

FID

Fidaxomicin

p1

Piscidin 1

p3

Piscidin 3

viii
p1Cu

Piscidin 1 Copper complex

p3Cu

Piscidin 3 Copper complex

SEM

Scanning Electron Microscope

SLP

Surface Layer Protein

EPS

Extracellular Polymeric Substances

GI

Gastrointestinal Tract

HDP

Host Defense Peptides

AMP

Antimicrobial Peptides

MRSA

Methicillin-Resistant Staphylococcus aureus

TAMRA

5-Carboxytetramethylrhodamine

ATCUN

Amino-Terminal Copper and Nickel-binding
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CHAPTER 1
INTRODUCTION
OVERVIEW
Bacterial Phenotypic Stress Responses
The prokaryotic organisms called bacteria are categorized by their relationship to
environmental oxygen [3]. Obligate aerobic bacteria require oxygen as the terminal electron
acceptor for energy generation and cannot live in its absence [4]. Facultative anaerobes can
either perform aerobic respiration in oxygen-rich environments or anaerobically generate energy
through fermentation. All anaerobes encode strong antioxidant defense mechanisms against
reactive oxygen species (ROS) generated by aerobic metabolism and respiration [5]. Obligate
anaerobic bacteria utilize carbon dioxide, sulfur, fumarate, or ferric acid rather than oxygen as
terminal electron acceptors and are quickly killed by oxygen exposure as they have limited
antioxidant capacity to detoxify ROS [3, 4]. Anaerobic pathogens infect oxygen-poor or anoxic
environments within hosts, such as the large intestine in mammals. Most anaerobic pathogens are
pathobionts and originate from commensal gut relationships to become infectious pathogens that
are major health concerns [6]. Bacteria experience a variety of stresses in their natural
environments, including stress from the host immune system in the case of pathogens [7].
Bacterial stress can lead to several adaptive and protective responses, altering gene expression
patterns and cell physiology [8, 9]. This can include the formation of resilient, metabolically
dormant spores or adherence to surfaces and secretion of a protective extracellular matrix to form
biofilm as a direct phenotypic expression in response to environmental stresses [10].
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Stressors in the pathogenic bacterial niche include but are not limited to antibiotics,
innate immune system effects such as the release of reactive oxygen species (ROS) and reactive
nitrogen species (RNS), gastrointestinal (GI) metal homeostasis, chemicals (such as sanitizers in
the food industry or in medical settings), physical stresses (temperature from fever in a host or
from industrial or healthcare sterilization processes), and competition for nutrients from other
bacteria; however, some highly resilient pathogens survive and thrive in these stressed
environments [11, 12]. Bacterial pathogenesis is an urgent health crisis around the world because
microbes have developed both genetic and phenotypic processes of evading stresses and are
increasingly antibiotic-resistant [13]. Studies already exist focusing on the regulation of
resistance genes with little attention to the phenotypes that result from gene transcription and
translation. It is the phenotypic changes that allow the infection to persist and cause symptoms in
the host [14]. This study focuses on phenotypic stress responses, namely spore production and
biofilm formation of the pathogenic anaerobic bacteria Clostridioides difficile.
Clostridioides difficile
Clostridioides (formerly Clostridium) difficile was first isolated and identified in 1935 by
Ivan Hall and Elizabeth O’Toole [15]. The pathogen was isolated during a study investigating
the bacterial flora in the stool samples of healthy infants [16]. C. difficile is the cause of
Clostridioides difficile infection (CDI). Symptoms of CDI can include inflammation of intestinal
walls, profuse diarrhea, and pseudomembranous colitis. CDI has been recognized as an urgent
world health crisis by the U.S. Center for Disease Control [17, 18]. Since its discovery,
Clostridioides difficile in the 21st century became the leading nosocomial infection around the
world. This opportunistic pathogen is responsible for over 462,100 cases resulting in 20,500
deaths annually in the United States alone [19]. The main risk factor for contracting CDI is the
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use of broad spectrum antibiotics, resulting in disruption of the gut microbiota [20]. This creates
an opportunity for C. difficile colonization, as the pathogen has less competition for nutrients.
Old age is an additional risk factor, as people over 65 years old are 8.65 times more likely to
contract CDI than those younger than the age [16].
Epidemiology data for the past two decades show that CDI is not only found in
developed countries, but also present in the African continent. Data show that on the African
continent, unlike in Europe and North America, younger people get CDI more than the elderly.
This is probably due to the high prevalence of co-morbid conditions such as tuberculosis,
particularly in west Africa [21]. C. difficile has primarily been a western hospital-acquired
disease, but the number of community-acquired infections has increased in recent years as have
cases in infants in developing nations [22, 23]. The severity of CDI has also increased during the
21st century with the emergence of so-called “hypervirulent” epidemic strains including the
R20291 strain responsible for the infamous 2003-2005 Stokes Mandeville hospital outbreak in
Great Britain. This hypervirulent strains are associated with higher levels of disease recurrence
and death in infected patients [24, 25]. C. difficile is resistant to several families of antibiotics
and it is becoming increasingly resistant to next-generation therapeutics including fidaxomicin,
metronidazole, and vancomycin [26]. Recently, the most clinically effective treatment for CDI is
the replenishment of the protective gut microbiota through fecal transplants. The procedures
have a high risk of introducing other pathogens, making them not recommended for
immunocompromised patients, so there is great interest in the development of new strategies for
prevention and treatment of CDI [27]. Few labs study C. difficile because it is a strict anaerobe
that requires an artificially created anaerobic atmosphere with in an anaerobic chamber (Figure
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1) [28]. Anaerobic experiments commonly occur in an atmosphere of 85% nitrogen, 10% CO2,
5% H2.

Figure 1. Representative image of an anaerobic chamber. The sealed glove box is accessed by a
vacuum airlock to allow the transfer of materials in and out of the chamber without filling it with
environmental oxygen. Shown is the Purcell lab anaerobic chamber.

Spores
C. difficile persists in the environment and infects new hosts in the form of metabolically
dormant spores, which are highly resilient to chemical and physical stresses and remain viable
for months [29]. Spore formation and germination are important for the spread of CDI but are
still not well characterized in C. difficile [30]. Spores germinate into vegetative cells which are
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the metabolically active and toxin-producing stage of the bacterial life cycle. Most known
regulatory information was adapted from Bacillus subtilis but many of the sporulation regulation
pathways are not conserved between the two species [31, 32]. Spores germinate into vegetative
cells and proliferate in the gut following exposure to germinants including primary bile acids
such as taurocholate and the amino acids alanine and glycine [33]. Antibiotic treatments disrupt
the intestinal microbiota, allowing C. difficile spores or vegetative cells to either germinate or
replicate easily because other competing microbes in the same niche die off, allowing C. difficile
greater access to bioavailable nutrients [34].
Spores are extremely difficult to eradicate from contaminated environments. The
resistance of bacterial spores results from a protective multilayered structure (Figure 2a) and
from the unique composition of the spore core containing highly dehydrated bacterial DNA,
ribosomes, dipicolinic acid (for maintenance of spore dormancy) and inorganic minerals (Figure
2b) [35, 36].

a

b

Figure 2. Structure of C. difficile spores. (a) Schematic drawing of longitudinal spore structure
and the multilayered spore coat. (b) Scanning Electron Microscope (SEM) image of aggregated
spores in the extracellular matrix of a biofilm. Adapted from Lawler, A. J., et al 2020
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The spore core is dehydrated which keeps DNA, tRNA, ribosomes, and metabolic
enzymes dormant or inactive until bile salt activation of spore germination [37]. The inner
membrane is the bridge between the core of the spore and the germ cell wall. The spore core
membrane is made up of derivative forms of cellulose which protect against desiccation and
prevents inlet of DNA damaging reagents [38]. The next layer is the cortex which is made of
peptidoglycans that are degraded by lytic enzymes during spore germination [39]. The outer
membrane only creates space between the rest of the layers. The spore coat consists of more than
30% water insoluble proteins creating an impermeable barrier to most biological substances [40].
Though not present in many other sporulating bacteria, the exosporium contributes to C. difficile
spore resiliency against well characterized stresses due to its high number of cysteine-rich
proteins necessary for resistance to lysozyme, ethanol, and heat treatment as well as surface layer
protein (SLP), which is involved in sensing bile salt germinants [41].
Primary bile salts, including cholic acid and chenodeoxycholic acid (Figure 3a), are
produced by liver hepatocytes and stored in the gallbladder before diffusing into the small
intestine, where they solubilize dietary lipids [42]. Intestinal bacteria metabolize primary bile
salts into secondary bile salts which accumulate in the large intestine (Figure 3b) before being
trafficked back to the liver and recycled into primary bile salts (Figure 3c) [43]. Primary bile
salts induce C. difficile spore germination while secondary bile salts inhibit C. difficile vegetative
growth [44]. Disruption of the gut microbiota reduces the conversion of primary bile salts to
secondary bile salts, creating conditions hospitable for C. difficile colonization [45].
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a

b

c

Figure 3. Synthesis of the major bile acids of human bile and circulation in the hepatic, biliary,
and digestive systems. (a) Bile acids are converted into bile salts by the association with metal
cations. Produced bile salts are stored in the gall bladder. After food ingestion, bile is released
into the small intestine. Bile acids are modified into secondary bile acids in the small intestine by
commensal microbiota. Primary and secondary bile acids are reabsorbed in the terminal ileum.
Modified from Fontana et al. (b) Bile acids can be conjugated with amino acids. In this example,
cholic acid becomes either taurocholic acid or glycocholic acid after conjugation with taurine or
glycine, respectively. (c) Bile acids are amphipathic; the hydrophobic side is associated with the
surface of lipid droplets while the polar groups interact with water creating a stable emulsion of
small, mixed micelles. Modified from Hofmann and Vander et al.
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Spores appear to have affinity for the extracellular matrix of biofilms, which may act as a
reservoir for them in vivo [46]. They can persist on surfaces or in patients’ intestines in hospital
and healthcare facilities for extended periods, leading to new or recurrent infections [47, 48].
Recurring episodes affect about 15–35% of patient and present a particular risk for the elderly
[34]. Spore germinate in the intestine is activated by cholate and deoxycholate stimulants [49].
Ingested C. difficile spores germinate into vegetative cells, which either reproduce and produce
toxins or differentiate into spores to continue the bacterial life cycle (Figure 4) [50].

Figure 4. Schematic representation of the C. difficile infection cycle. Spores are ingested and can
pass the gastric barrier to reach the intestine. In the intestine, when the normal gut microbiota is
disturbed, for example by antibiotic treatment, the concentration of the secondary bile salts
cholate (CA) and chenodeoxycholate (CDCA) increases and spores will germinate. Spore
germination produces a population of vegetative, actively growing cells, which will initiate toxin
production and sporulation. Shedding of the highly resistant spores will allow their accumulation
in the environment and the infection of new hosts, and spores retained in the host can cause
recurrence. Reproduced from Isidro Mendes et al 2017.
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Bacterial Biofilms
The mammalian gastrointestinal tract (GI) is home to a complex community of microbes,
composed of prokaryotes and eukaryotes, collectively referred to as the GI microbiota, that are
present mostly as biofilms [51]. Biofilm can protect vegetative bacterial cells and harbor spores
[46]. Formation attached of biofilms involves secretion of biofilm components like matrix and
adhesins at high cell density as shown in Figure 5 [52]. The biofilm matrix includes
polysaccharides, proteins, and nucleic acids, together called extra polymeric substances (EPS)
[53, 54]. Some extracellular conditions, such as carbohydrate availability or antibiotic exposure,
can stimulate increased biofilm formation [55]. After maturation, the biofilm can disperse
vegetative cells and spores [56]. We explore sporulation and biofilm formation of planktonic C.
difficile cells in response to antibiotics, antimicrobial metals, antimicrobial peptides, and
oxidants that mimic stressful environments within a mammalian host.
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Figure 5. Schematic representation of biofilm formation. Formation begins with a reversible
attachment of planktonic cells (brown ovals) followed by the adhesion to the surface (grey) (1).
The bacteria then form a monolayer and irreversibly attach by producing an extracellular matrix
(yellow) (2). Next, a microcolony containing multiple layers is formed (3). During later stages,
the biofilm is mature, forming characteristic “mushroom” structures (4). Finally, some cells start
to detach, and the biofilm (shown in yellow) will disperse (5). Adapted from Vasudevan, 2014.

Antimicrobial Peptides (AMPs)
Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are a
common endogenous defense mechanism against pathogens, which occur in all classes of life.
AMPs are relatively small peptides consisting of 4−50 amino acid residues and are highly
cationic [57]. Piscidins are antimicrobial HDPs found in fish which have previously shown
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broad-spectrum antimicrobial activity against aerobic bacteria [58]. They can induce
immunomodulatory effects by enhancing the immune system’s ability to attract leukocytes to the
infection and directly kill bacteria by attacking plasma membranes or targeting intracellular
DNA with nuclease activity [59-61]. These antimicrobial peptides are promising therapies,
because they are active against highly drug resistant bacteria [58].
The peptides employed in these investigations are piscidin 1 (p1)
(FFHHIFRGIVHVGKTIHRLVTG) and piscidin (p3) (FIHHIFRGIVHAGRSIGRFLTG).
The peptides fold into alpha helical secondary protein structures (Figure 6) and are derived from
the mast cells of hybrid striped sea bass, which exhibit broad spectrum antibacterial activities
with dual mechanisms [62, 63]. Both piscidins have conserved amino terminal copper and nickel
binding (ATCUN) motifs that can bind +2 transition metals, most notably copper (II) and nickel
(II). The ATCUN regions for p1 and p3 are FHH and FIH, respectively [61, 64]. p1 primarily
disrupts the bacterial cell membrane and exhibits weak DNA nuclease activity while p3 causes
less membrane disruption and displays strong DNA nuclease activity [58]. There are two
proposed models for piscidin-mediated membrane disruption. The first is that piscidins enter the
membrane perpendicular to the membrane lipids and disrupt contacts between the lipids through
a combination of hydrophobic and hydrophilic interactions. [63]. Additionally, their bound
copper ions induce oxidative stress by inducing the formation of ROS, which cause oxidative
damage to the lipid headgroups [63]. These interactions have been studied in the presence of
atmospheric oxygen levels but had not previously been studied in the absence of molecular
oxygen. In this work, we investigate the efficacy and response of these peptides against
Clostridioides difficile in an anaerobic environment, focusing on the bacterial cells’ proliferation,
viability, sporulation, and biofilm production.
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Figure 6: Structure of piscidin 1. Piscidins form amphipathic alpha-helices that interact with the
plasma membranes. The structure of piscidin 1 was determined by solid-state NMR. ( PDB
CODE: 6PF0). Adapted from Cotten M. L et al 2019.

Common Antibiotics
C. difficile has supplanted methicillin-resistant Staphylococcus aureus as the most
common cause of nosocomial infection [65]. Antibiotics commonly used in the treatment of CDI
now include fidaxomicin (FID), vancomycin (VAN) and metronidazole (MET), but resistance to
all these drugs is rising over time [66]. These antibiotics have different cellular targets.
Fidaxomicin binds to a four amino acid sequence on the C. difficile RNA polymerase, which is
not broadly conserved among the commensal gut bacteria, to inhibit the initiation of RNA
transcription with high specificity (Figure 7) [1, 67]. Metronidazole denatures genomic DNA
and causes strand breakage by intercalating into the helical fold and also induces oxidative
damage (Figure 7) [1, 68]. Vancomycin inhibits the biosynthesis of the major structural cell wall
polymer, peptidoglycan, interfering with cell growth and replication (Figure 7) [1, 69]. Many of
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other classes of commonly used antibiotics, including fluroquinolones and tetracycline, are
ineffective against C. difficile; their interactions with C. difficile are summarized in Table 1 [70].
Currently, MET is rarely used in developed countries because many strains of bacteria
are now resistant to it; the same issue is beginning to affect VAN, which is a non-ideal treatment
for CDI because it is not narrow spectrum. A narrow spectrum antimicrobial agent are genus or
species specific in action because they target or are more suited to inhibit species specific
process [71]. FID is the most recent and specific treatment for CDI but has a very high cost and
there are already some clinical isolates of C. difficile with low susceptibility to this antibiotic
[66]. There is an urgent need for new and highly specific therapeutic methods or combination of
methods for treatment of CDI that bacteria will not easily develop resistance against.

a

b

c

Figure 7. Current antibiotic treatments primarily used to treat C. difficile infection: (a)
metronidazole, (b) vancomycin, and (c) fidaxomicin. Adapted from Jarrad et al 2015 [1].
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Table 1. Summary of Clostridioides difficile resistance to antibiotics and associated
mechanisms. Adapted and modified from Isidro and Mendes et al 2017.
Antibiotic

Mechanism

Relevance in CDI

Metronidazole

DNA damage
after reduction of
metronidazole
inside the
bacterial cell

Treatment of
mild/moderate
CDI

Vancomycin

Inhibition of cell
wall synthesis by
binding to the
dipeptide D-AlaD-Ala of
peptidoglycan
Inhibition of RNA
synthesis by
binding to RNA
polymerase (in a
site distinct from
rifamycin)
Inhibition of DNA
synthesis by
binding to DNA
gyrase and
topoisomerase IV

Treatment of
severe and
recurrent CDI

Moderate

Treatment of
severe and
recurrent CDI

Rare

Mutations in
rpoB, rpoC and
rarR

Associated with
elevated risk of
CDI; resistance
contributed to
spread of the
epidemic ribotype
027
Used adjunctively
for the treatment
of recurrent CDI
Resistance found
in multi-resistant
isolates; resistance
shared between
human and swine
isolates
Resistance
associated with
prevalent
ribotypes

High

Target
modification by
mutations in gyrA
and gyrB

Common

Target
modification by
mutations in rpoB
Target protection
by tetM, carried
by the elements
Tn5398 or Tn916like

Fidaxomicin

Fluoroquinolones

Rifamycin

Tetracyclines

Chloramphenicol

Inhibition of RNA
synthesis by
binding to RpoB
Inhibition of
protein synthesis
by binding to 30S
ribosomal subunit

Inhibition of
protein synthesis
binding to the 50S
ribosomal subunit

Resistance
frequency
High

Common

Uncommon

Mechanism of
resistance
Multifactorial 5nitroimidazole
reductase and
modifications in
multiple proteins
involved in DNA
repair, iron uptake
and metronidazole
reduction
Mutations in
murG

Inactivation of the
antibiotic by catD,
carried by Tn4453
elements
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The Human Gastrointestinal Tract
The gastrointestinal (GI) tract consists of the esophagus, stomach, small intestine
(duodenum, jejunum, and ileum), large intestine (colon the ascending colon and cecum) and the
rectum, which include a continuous tube; each part of the GI tract comes together to act in
concert for the digestion of food. The GI tract is home to millions of microbes (Figure 10) [72].
In recent years, studies have confirmed that the human GI microbial community, or microbiota,
play a significant role not only in food digestion but also in immune system function [73].
Alterations in GI microbial composition are strongly associated with many intestinal diseases,
including colorectal cancer and inflammatory bowel disease as well as CDI (Figure 8). The small
intestine is the major site of digested food absorption and is the location where C. difficile spores
encounter their bile acid germinants [74]. Peristalsis, the contractile movement of the digestive
tract, moves the majority of these germinated spores to the large intestine, which is an anaerobic
environment with < 2 % oxygen [75]. If the commensal gut microbiota have not consumed all
of the food sources for C. difficile, the germinated spores can proliferate in the proximal colon
where the C.difficile permeate through the mucosa, appear to adhere to the epithelial tissue
(Figure 8), and secrete toxins that cause intestinal inflammation (Figure 9) [2, 76, 77].
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Figure 8. C. difficile spores and vegetative cells adhere to the host intestinal epithelium. Falsecolor, high resolution, scanning electron micrograph of a C. difficile spore (blue) and vegetative
cell (red) adhering to human intestinal epithelial cells (green) grown in culture. Microvilli are
clearly visible (feather-like green protrusions). Micrograph collection, Vedantam laboratory [2]
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Figure 9. C. difficile adheres to sites of intestinal damage in infected mice. (i–ii)
Hematoxylin (a basic dye) and eosin (an acidic dye) double edge staining of cecal biopsies
where hematoxylin stains the nuclear components and eosin stains the cytoplasm components
from (i) healthy, clindamycin-treated mice and (ii) mice infected with C. difficile 027/BI-7day 49 post-infection. Scale bars represent 100 mm. (iii-iv) Scanning electron micrographs
illustrating the presence of C. difficile microcolonies (iii) and biofilm-like structures (iv) on
the intestinal mucosal surface (or epithelial cells of the same mice). Adapted from Lawley et
al 2012
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Figure 10. The human gastrointestinal tract. Shown are the organs of the human gastrointestinal
tract and a summary of their biological roles. Adapted from Koziolek et al 2019
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RESEARCH AIMS
The main objectives of the work presented in this dissertation are to:
1. Determine the efficacy of piscidins and their copper complexes against Clostridioides
difficile in anaerobic conditions using growth inhibition assays, where peptides are
applied before cells are inoculated into medium and time kill assays, where peptides are
added to growing cells and viability is measured for each time (Chapter II).
2. Investigate synergistic or antagonistic effects between piscidins and different classes of
antibiotics used to treat Clostridioides difficile using growth inhibition assays (Chapter
III).
3. Determine the effect of piscidins and other environmental stresses on Clostridioides
difficile phenotypic stress responses by quantitating sporulation and biofilm production
(Chapters III and IV).
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CHAPTER II
EFFICACY OF ANTIMICROBIAL PEPTIDES PISCIDINS AND THEIR COPPER
COMPLEXES AGAINST C. DIFFICILE IN ANAEROBIC CONDITONS
PREFACE
The content in this chapter is reprinted with the permission from “Oludiran, A.; Courson,
D.S.; Stuart, M.D.; Radwan, A.R.; Poutsma, J.C.; Cotten, M.L.; Purcell, E.B. How Oxygen
Availability Affects the Antimicrobial Efficacy of Host Defense Peptides: Lessons Learned from
Studying the Copper Binding Peptides Piscidins 1 and 3. Int. J. Mol. Sci. 2019, 20, 5289.
https://doi.org/10.3390/ijms20215289”. Permission is provided in Appendix G. Reported is a
modified version of the published manuscript.
OVERVIEW
Clostridioides (formerly Clostridium) difficile infection (CDI), whose symptoms can include
inflammation, profuse diarrhea, and pseudomembranous colitis, has been recognized as an urgent
public health threat in the United States and other industrialized nations [17]. CDI is primarily a
hospital-acquired disease, as disruption of the native gut microbiota by prior antibiotic usage is
the major risk factor for C. difficile colonization, although the number of community-acquired
infections has increased in recent years [22]. The severity of CDI has also increased during the
21st century with the emergence of so-called “hypervirulent” epidemic ribotypes of the
bacterium, most notably ribotype 027, that are associated with higher levels of disease recurrence
and death in infected patients [24]. C. difficile is resistant to several families of antibiotics,
including penicillin-family beta lactams and fluoroquinolones, and is increasingly resistant to
next-generation therapeutics including fidaxomicin and vancomycin [26, 78]. Currently, the most
clinically effective treatment for CDI is replenishment of the protective gut microbiota through
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fecal transplants. As these procedures have a high inherent risk of introducing uncharacterized
pathogens and are not recommended for immunocompromised patients, there is great interest in
the development of new strategies for prevention and treatment [79]. C. difficile persists in the
environment in the form of metabolically dormant spores, which are highly resilient to chemical
and physical stresses and remain viable for months [29]. If mammals ingest these spores, amino
acids and bile salts in the digestive system trigger their germination into metabolically active
vegetative cells [80].
Vegetative C. difficile often cannot integrate well into the diverse, metabolically efficient
microbial ecosystem of a healthy intestinal microbiome but can take advantage of the loss of
bacterial species diversity and rise in nutrient availability induced by antibiotic exposure to
establish colonization [81]. C. difficile colonization triggers the innate immune response,
including the release of reactive oxygen species (ROS) and cationic host defense peptides
(HDPs) [82]. These antimicrobial peptides can kill bacterial cells directly through several
mechanisms, attacking the cell membrane and/or intracellular targets, and indirectly by
activating the host’s innate immune response [83]. As these peptides have multiple cellular
targets, bacteria cannot quickly develop or transmit genetically encoded resistance to them, and
they are a promising precursor for the development of stand-alone antibiotics or adjuvants
designed to work synergistically with existing antibiotics [84, 85].
The antimicrobial peptides piscidins are a family of HDPs found in teleost (bony) fish
species with demonstrated efficacy against a wide range of bacteria and viruses. The piscidins p1
and p3, which are derived from the mast cells of hybrid striped sea bass, exhibit broad spectrum
antibacterial activity although their mechanisms of action differ [86]. Both peptides localize to
bacterial cell membranes and are internalized at sub-lethal concentrations. While p1 is more
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damaging to membrane integrity than p3, the latter is more disruptive to DNA [64]. Furthermore,
studies done on live bacteria and model membranes indicate that the peptides, especially p1, take
advantage of lipid heterogeneity to deploy their mechanism of membrane disruption [64, 87].
Recently, it was demonstrated that under aerobic conditions both peptides use their aminoterminal copper and nickel-binding (ATCUN) motifs to coordinate Cu2+ with picomolar affinity
[58, 88]. Piscidin-copper complexes form ROS and exhibit nuclease activity against double
stranded DNA, resulting in increased lethality against multiple bacterial species [58]. Such
copper-ATCUN complexes can serve as sources of oxidative stress, increasing peptide lethality
against bacteria in an aerobic environment [89].
Oxidative stress can be harmful or lethal to organisms, depending on their oxidative stress
tolerance. Obligate anaerobes such as Clostridia are considered completely intolerant to oxygen,
although they can employ scavenger and reductase enzymes to survive transient exposure to
environmental oxygen or immune-mediated oxidative bursts [29, 81, 90]. Application of
antimicrobial peptides sensitizes C. difficile to antibiotics, although epidemic strains from
ribotype 027 are less sensitive than other strains [85, 91]. Importantly, as HDPs, piscidins have
immunomodulatory effects. Our investigations have demonstrated that both p1 and p3 induce
chemotaxis in neutrophils [88]. These effects are exclusively mediated by formyl peptide
receptors 1 and 2 (FPR1 and FPR2), both of which are G-protein coupled receptors (GPCRs) that
play crucial functions in the immune system [92-96]. Interestingly, Cu2+-coordination decreases
the chemotactic effects of p1 and p3, suggesting a regulatory effect of copper between the direct
and indirect antimicrobial effects of the peptides [88]. Given the role of FPR2 for the resolution
of inflammation, it has become an important drug target [92]. p1 has also been shown to decrease

23
the inflammatory response through a process that may involve binding lipopolysaccharides and
decreasing toll-like receptor (TLR)-mediated inflammatory pathways [97, 98].
The immunomodulatory properties of HDPs such as piscidins have emerged as an important
topic of research given that these effects are indirect, and thus unlikely to activate mechanisms of
drug resistance observed with traditional antibiotics that directly attack bacteria [59]. In addition,
HDP modulation of the inflammatory immune response can mitigate infection symptoms and has
been shown to reduce toxin-dependent inflammation in mouse models of C. difficile infection
[99]. As indicated above, the antimicrobial effects of piscidin have previously been measured in
aerobic environments. However, there is a ten-fold range of partial oxygen pressure among the
tissues of the human body, with organs such as the large intestine providing a habitat for
anaerobic microbes, both commensal and pathogenic [100].
Here, we report that the antimicrobial activity of p1 and p3 differ in aerobic and anaerobic
environments. In an anaerobic environment, both p1 and p3 are incorporated into C. difficile
cells, inhibit bacterial proliferation, and are highly toxic against actively dividing C. difficile.
Both peptides associate extensively with bacterial cell membranes, exhibiting preferential
localization at sites of high curvature such as cell poles and septa. In contrast to previously
observed aerobic data, anaerobic piscidin antibacterial activity does not appear to be enhanced by
metal complex formation. Our findings suggest that the mechanism by which these peptides
induce bacterial cell death is influenced by the availability of environmental oxygen. Future
mechanistic investigations of HDPs focused on potential medical applications must account for
oxygen levels at the desired site of action to accurately model antimicrobial activity.

24
MATERIALS AND METHODS
Materials, Chemicals, Bacterial Strains and Growth Conditions
Materials and chemicals were purchased from Fisher Scientific (Hampton, NH, USA)
unless otherwise indicated. The bacterial strains used in this study are listed in Appendix D. C.
difficile 630∆erm and R20291 were maintained on brain-heart infusion supplemented with 5%
yeast extract (BHIS) agar plates and liquid cultures were grown in TY medium [101, 102]. All
anaerobic bacterial culture took place at 37 ◦C in a Coy anaerobic chamber (Coy Laboratory
Products, Grass Lake, MI) with an atmosphere of 85% N2, 10% CO2, 5% H2. All plastic
consumables were allowed to equilibrate in the anaerobic chamber for a minimum of 72 h.
Growth Inhibition Assays
C. difficile was grown overnight and re-inoculated in fresh TY medium to log phase in a
Coy anaerobic chamber in an 85% nitrogen, 10% CO2, 5% H2 environment. Two-fold dilution
series of TY medium containing the indicated concentrations of peptide and/or copper salts were
prepared in sterile 96-well plates as detailed in Wiegand et al [103]. Wells containing 200 µL of
medium were inoculated with 20 µL of saturated overnight culture of C. difficile 630∆erm or
R20291 containing approximately 108 CFU/mL and incubated anaerobically for 16 h at 37 0C.
Closed microplates were removed from the anaerobic chamber and the outsides of the plates
were disinfected with 10% bleach before examination to determine the minimum concentration
of each peptide and/or metal ion sufficient to completely inhibit visible growth. Culture density
at 630 nm was measured in a BioTek (Winooski, VT, USA) microplate reader. As removal from
the anaerobic chamber killed the anaerobic C. difficile bacteria, we were not able to plate
samples to determine CFU/mL after spectroscopic measurements. Inhibitory concentrations were
reported as the peptide concentration necessary to reduce the overnight OD630 by at least 50%
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from that of untreated samples. Data reported are the means and standard deviations of four
biologically independent samples in duplicates.
Time-Kill Assays
3mL of TY media were inoculated with single colonies of C. difficile R20291 and allowed to
grow at 37 0C to an optical density at 600 nm (OD600) of 0.5–0.7. At the onset of the experiment
20 µL aliquots were removed from the exponentially growing culture and inoculated into fresh
TY medium containing the indicated concentration of peptide and/or copper sulfate (CuSO4).
The final volume was adjusted to 1 mL with fresh TY medium. After 0, 0.5, 2, and 4 h of
incubation at 37 0C, 10 µL aliquots were removed for serial 10-fold dilution in TY. 106 dilutions
were plated in duplicate on BHIS agar plates for colony enumeration. Colony forming units
(CFU) were counted after 24 h. Data reported are the averages of three biologically independent
samples measured in duplicate. Treated samples were compared to untreated samples and to each
other by two-way ANOVA using Tukey’s multiple comparison test with Prism (GraphPad
Software, San Diego, CA, USA).
Microscopy
Live-cell, time-lapse, wide-field fluorescence, and differential interference contrast (DC)
microscopy of the interaction between TAMRA-labeled piscidin peptides and C. difficile R20291
bacteria was performed on a Nikon Ti-E inverted microscope equipped with apochromatic TIRF
60X oil immersion objective lens (N.A. 1.49), pco.edge 4.2 LT sCMOS camera, and SOLA SE II
365 Light Engine as well as complementary DIC components (Nikon Instruments Inc, Melville,
NY, USA). Mid-logarithmic phase cells and peptides at the indicated concentration were mixed
inside the anaerobic chamber and injected into home-built anaerobic rose-type imaging chambers
as previously described [104]. Imaging chambers were removed from the anaerobic chamber and
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placed on the microscope after sterilization. The microscope was maintained at 37 ◦C using a
home-built enclosure and a Nevtek Air Stream microscope stage warmer (Nevtek, Williamsville,
VA, USA). Nikon Perfect Focus system (Nikon Instruments Inc, Melville, NY, USA) was
employed to eliminate focal drift during recordings. Movies consisting of a fluorescence and
DIC image each minute for 60 min were then recorded for each condition. Movies started 6–8
min after the bacteria and peptide were mixed. Data analysis was performed using the Nikon
Elements imaging suite. During the recordings, the amount of fluorescence background
increased with time, presumably as peptide was deposited on the coverslip surface. During
analysis, this background change was corrected using background-leveling tools, then a second
rolling-ball type background correction was used to remove imaging artifacts. A threshold binary
mask was then applied to the fluorescence images to isolate and count each fluorescent object
(peptide-labeled bacteria) in the movie. Fluorescence levels of objects were monitored as a
function of time.
Flame Atomic Absorption Spectroscopy
Flame atomic absorbance spectroscopy (FAAS), the copper concentration in TY medium was
measured using an AA-7000 atomic absorption spectrophotometer (Shimadzu Scientific
Instruments, Columbia, MD, USA) with a hollow cathode lamp using an acetylene flame [105].
Copper from TY medium was detected at 324.8 nm and quantified using a standard curve of
copper chloride (CuCl2) diluted in water.
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RESULTS
Piscidins Prevent C. difficile Proliferation
To measure the inhibitory effects of piscidin peptides on C. difficile growth we inoculated
C. difficile strains 630∆erm and R20291 into a medium containing the peptides. C. difficile
630∆erm is an erythromycin-sensitive derivative of the reference strain C. difficile 630, while
R20291 is an epidemic strain isolated from a 2003–2005 hospital outbreak of C. difficile
infection in the United Kingdom [106, 107]. R20291 is a so-called “hypervirulent” strain of
ribotype 027 and is more resistant than 630 to multiple classes of antibiotics including
clindamycin and ciprofloxacin [108]. The presence of piscidin peptides prevented C. difficile
proliferation. Notably, R20291 was as susceptible as 630∆erm to growth inhibition by piscidins.
p1 inhibited proliferation of both strains at concentrations at or above 4.00 µM and p3 inhibited
growth at or above 8.00 µM (Figure 11).
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Figure 11. Piscidins inhibit C. difficile growth. Optical densities of overnight C. difficile
630∆erm and R20291 cultures grown in the presence of the indicated concentrations of piscidins.
Data shown are the means and standard deviations of four biologically independent samples
triplicates. The figure is reproduced from Oludiran et al. 2019.

Piscidins Are Incorporated into C. difficile and Appear to Localize to Sites of Membrane
Curvature
Confocal microscopy of fixed bacterial cells exposed to fluorescently labeled p1 and p3
has previously shown that they enter both Gram-negative and Gram-positive bacterial cells and
appear to be concentrated at bacterial nucleoids and cell septa [64, 87]. We exposed live C.
difficile R20291 cells to 0.75 µM 5-carboxytetramethylrhodamine (TAMRA)-labeled p1 and p3
and observed peptide uptake and localization in unfixed live cells. As C. difficile exhibits green
autofluorescence, the red TAMRA labeling was distinct from any intrinsic signal produced by
the cells [109]. Exponential-phase cells and peptides were mixed and sealed within microscopy
chambers in an anaerobic chamber and then transported to the microscope, resulting in a 6-min
delay between the onset of peptide exposure and the first image [104]. Mean fluorescence
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intensity within cells was stable over the course of 1 h of monitoring, indicating that peptide
incorporation into cells occurs within the first few min of exposure (Figure 12a,b). Peptide
integration appeared to be complete within 6 min even at lower peptide concentrations of 0.25
and 0.075 µM (data not shown). The addition of additional unlabeled peptide or unlabeled
peptide complexed with Cu2+ did not increase fluorescence intensity, and thus there was no
evidence of potential cooperativity in peptide uptake. There were distinct fluorescent puncta at
the septa of provisional cells (Figure 12 c,e,f), consistent with prior observations in Escherichia
coli (E. coli) and Bacillus megaterium (B. megaterium) [64]. In addition, there were fluorescent
puncta at cell poles, suggesting that piscidin generally localize to sites of high curvature (Figure
12d). While unlabeled cells were motile and maintained rod-like shapes, many of the
fluorescently labeled cells exhibited curvature or surface irregularities suggestive of cell
envelope damage (Figure 12e). Performing these experiments on live cells allowed real-time
observation of cellular response to peptide intoxication. We observed a motile chain of
provisional rod-shaped cells over the course of 10 min (Figure 12g). During this time, the chain
of cells took up labeled p1 at one pole and subsequently developed progressively severe
curvature at cell septa and separated into smaller fragments (Figure 12g). The resulting pieces
were asymmetrically curved and non-motile, indicating that lysis rather than healthy cell division
had occurred.

30
a

c

f

d
b

e

g

Figure 12. Incorporation of TAMRA-piscidin into live C. difficile. (a, b) Fluorescent signal
per cell of 0.75 μM TAMRA-labeled p1 (a) and p3 (b) mixed with live C. difficile R20291.
Cells had already reached maximum peptide incorporation by the time recording began,
roughly 6 min after peptides and cells were mixed. The addition of unlabeled peptide, in the
presence or absence of equimolar amounts of copper sulfate, did not cooperatively increase
peptide incorporation. (c-f) Representative images of C. difficile labeled with: (c) 0.75 μM
TAMRA-labeled p1 plus 0.75 μM unlabeled p1; (d) 0.75 μM TAMRA-labeled p3; (e) 0.75 μM
TAMRA-labeled p1 plus 2.25 μM unlabeled p1; (f) 0.75 μM TAMRA-labeled p1 plus 0.75 μM
unlabeled p1. (g) Time course showing the rupture of a divisional cell labeled with 0.75 μM
TAMRA-labeled p1 plus 0.75 μM unlabeled p1. Scale bars in the panels (c-f) represent 10
microns. The scale bar in panel (g) represents 5 microns and this figure is reproduced from
Oludiran et al 2019.
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Piscidins Reduce Established C. difficile Populations
Growth inhibition assays do not distinguish between substances that kill cells and
bacteriostatic substances that inhibit growth only if compounds are present in sufficient
quantities prior to bacterial proliferation. To confirm that piscidins can reduce the number of
viable cells in established bacterial populations, we performed time-kill assays to confirm that
the number of viable C. difficile R20291 cells in exponentially growing culture decreases with
exposure to p1 and p3 at sub-inhibitory concentrations. As shown in Figure 13, both p1 and p3
reduce C. difficile viability at half of the concentration needed to inhibit bacterial growth.
The addition of 2.00 μM p1 significantly reduces the number of viable cells in the culture within
30 min, with continued loss of colony forming units over the course of 4h (Figure 13a).
Similarly, incubation with 4.00 μM p3 significantly reduced the number of viable cells within 30
min (Figure 13b). The presence of copper did not enhance bacterial killing by piscidins, in
contrast to what had previously been reported against E. coli and Pseudomonas aeruginosa (P.
aeruginosa) in aerobic condition [58]. To define the effects of copper alone against C. difficile,
we determined that the copper concentration of the TY growth medium used to culture C.
difficile under anaerobic conditions is 1.46 μM, which is lower than that of the Mueller-Hinton
broth previously used to culture E. coli and P. aeruginosa under aerobic conditions [58, 110].
We found that copper salts are capable of inhibiting C. difficile growth at the same
concentrations used for both p1 and p3 (Figure 13c). This means that copper alone at the
indicated concentration can still inhibit exponentially growing C. difficile anaerobically but
inhibition and killing of C. difficile were not enhanced by the addition of Cu2+ to either of the
peptides in anaerobic conditions. By contrast, in aerobic environments the bacterial response to
piscidins with Cu2+ is of higher killing than either the peptides or Cu2+ alone [57]
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Figure 13. Copper does not accelerate anaerobic C. difficile killing by piscidins. Time-kill
assays compared viable colony forming units per milliliter (CFU/mL) of bacterial culture
before exposure to p1 (a) and p3 (b) the CFU/mL 30 min, 2, and 4 h post-exposure. Cells
were exposed to peptides (p1 and p3), peptides, and equimolar copper sulfate added
simultaneously (p1 + Cu and p3 + Cu), peptides were allowed to form piscidin-copper
complexes in aerobic prior to addition to the anaerobic bacterial cultures ((p1Cu) and
(p3Cu)). (c) Time-kill assays comparing viable colony forming units per milliliter (CFU/mL)
of bacterial culture before exposure to the indicated concentrations of copper sulfate with the
CFU/mL 30 min, 2, and 4 h post-exposure. CFU/mL in treated samples were compared to
those in untreated samples and to each other using two-way ANOVA with Tukey’s post-test
comparison. nt, not treated; n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; ****
p < 0.0001. This figure is reproduced from Oludiran et al 2019.
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Figure 14. Copper is still antimicrobial in anaerobic environments. (a) The copper concentration
of TY medium is 1.46µM as determined by comparison to a standard curve. (b) Optical densities
of overnight C. difficile 630∆erm and R20291 cultures grown in the presence of the indicated
concentrations of copper sulfate. Data shown are the means and standard deviations of four
biologically independent samples and this figure is reproduced from Oludiran et al 2019.

DISCUSSION
The development of new therapies to combat antibiotic-resistant infections, including C.
difficile infection, is an urgent public health priority. Antimicrobial peptides capable of
simultaneously killing bacterial pathogens and stimulating the host innate system are a promising
avenue for the development of new antimicrobial therapies. Piscidins previously showed efficacy
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against Gram-negative and -positive bacteria in aerobic environments [58]. Here, we investigated
their effect on anaerobic bacteria. While piscidins are still highly lethal against C. difficile
growing anaerobically, we found that piscidin growth inhibition and killing against C. difficile
were not enhanced by the addition of Cu2+. This is true even though copper alone is capable of
inhibiting C. difficile growth and killing actively growing C. difficile cells. While in aerobic
environments, the bacterial response to piscidins with Cu2+ is greater than that to either piscidins
or copper alone, it appears that the anaerobic response to piscidin with copper is less than the
sum of the parts, and thus does not feature the synergistic effects observed aerobically.
Bacteria employ general stress response pathways which can be activated by multiple
diverse extracellular stresses. Bacterial cells that have previously been exposed to an
extracellular stress such as antibiotic exposure may respond through phenotypic expression like
spore formation to go into dormant state [111, 112]. The fact that the C. difficile strains 630erm
and R20291 exhibit identical inhibition in response to p1 and p3, but differential inhibition to
copper alone, suggests that piscidins and copper inhibit bacterial growth and viability by
different mechanisms. This makes sense because Cu2+ has no specificity while piscidins have
specific targets. It should be noted that free Cu2+ in vivo is highly toxic to mammalian as well as
bacterial cells, and complexation by HDPs such as p1 and p3 can provide the critical specificity
of targeting the metal ions to bacterial rather than host cells. HDPs are a viable treatment option
against both aerobic and anaerobic bacteria, and in the case of C. difficile, it is extremely
encouraging that the epidemic strain R20291 is just as susceptible to HDP inhibition and killing
as the less robust 630∆erm strain. As the symptoms of C. difficile infection are inflammatory,
and treatments based on piscidins could potentially reduce inflammation while killing the
causative pathogen, this is a very promising strategy to pursue. However, while clinical
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antibiotics derived from HDPs would benefit from the inclusion of copper in tissues with
elevated levels of oxygen, such as the lungs, antibiotics targeted to less aerobic tissues, such as
the kidneys or large intestine, may not. Future work to investigate the interaction of piscidins
with C. difficile in animal models of infection will be necessary to determine whether copper
could or should be included with the peptides. More broadly, it appears that clinical treatments
developed from HDPs should be designed in a tissue-specific manner, as metal ion adjuvants
may be beneficial or necessary in some organs and unneeded in others, based on the oxygen
levels at the site of activity
Summary
We have established that the antimicrobial peptides piscidin 1 and 3 and their coppercomplexes have strong efficacy in anaerobic conditions. They significantly reduced the
proliferation of C. difficile and reduced previously established C. difficile populations. We
discovered that in anaerobic environments, coordinated or complexed copper does not increase
piscidin efficacy, even though copper alone is toxic to the bacterial cells at high concentrations.
The FAAS result showed that the amount of copper in the media is not enough to inhibit C.
difficile growth or viability without supplementation. The microscopy images indicate the
localization points of the fluorescently labeled peptides on the bacterial cells.
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CHAPTER III
PISCDINS AND THEIR COPPER COMPLEXES SENSITIZE C. DIFFICILE TO
ANTIBIOTICS AND SUPPRESS SPORULATION IN BACTERIAL CELLS
OVERVIEW
Bacteria need to survive stresses in their natural environments [7]. Environmental stress can
lead to several adaptive and protective responses, which can induce gene regulation and cell
physiological changes [8, 9]. These can include increased replication, formation of biofilm on
surfaces, altered metabolism, or dormancy (which in some Gram-positive Firmicutes bacteria
takes the form of sporulation) [113]. C. difficile is an anaerobic Gram-positive spore and biofilmforming pathogen that causes serious disease in humans [114]. C. difficile infection (CDI) is now
established as a growing health challenge in both developed and developing countries of the
world [115]. CDI predominantly affects long-term hospital inpatients, the elderly, immunecompromised patients, and people undergoing prolonged antibiotic treatments or exposure. The
symptoms of CDI include but are not limited to the inflammation of intestinal walls, profuse
diarrhea, and pseudomembranous colitis in human [116, 117]. This bacterium remains a leading
nosocomial pathogen, which is strenuous to healthcare systems.
C. difficile can form spores, highly resistant to environmental assaults, with a very serious
role in both the persistence and transmission of infection [35]. Any therapeutic agents that can
reduce C. difficile spore production could significantly minimize the transmission and relapse of
the C. difficile infection. In 2014, epidemiological data showed that C. difficile has surpassed
methicillin-resistant Staphylococcus aureus (MRSA) as the most common hospital-acquired
infection with high rates of recurrence and readmission. In an analysis of nationwide hospital
readmission data 2013 to 2017, 48.5% of patients had MRSA and 22% were readmitted to the
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health care center for the same infection, while 50% of patients had hospital-acquired CDI and
27% were readmitted with the same infection [118]. C. difficile spores are dormant and do not
require active ATP consumption for any metabolic processes [31]. In the presence of germinants,
including bile salts such taurocholic acid, and amino acids, and especially if antibiotic treatments
have killed off other bacteria, spores can develop into free-living vegetative cells which are the
toxin-producing stage of the bacterium’s life cycle [33]
Dormant spores can survive for months in an hostile environment with the help of their
protective multilayered structure [35]. Spores are extremely robust and resistant to both chemical
and physical attacks enabling C. difficile to survive exposure to heat, low levels of oxygen,
alcohol, and many disinfectants and spread to new patients in households and health care
facilities. Reports on C. difficile spores have implicated genes including csiA, which is involved
in the control of sporulation initiation in C. difficile and the master regulator spo0A which is the
main regulatory protein controlling sporulation, as factors which increase the spore formation in
this bacterium [119]. C. difficile spores are the cell form that spread infection, and mutants with
defective spore formation have a low infection rate [35, 76].
The antibiotic metronidazole (or nitroimidazole in its reduced form) inhibits nucleic acid
synthesis by disrupting the DNA of the cells [120]. The antibiotic vancomycin inhibits cell wall
synthesis [33]. Fidaxomicin is the most recent and well-known antibiotic treatment for CDI, yet
it comes at a high cost and there are still reports of recurrencies after treatment [121]. Some
newly isolated clinical strains of C. difficile harboring the rpoBV1143D allele have shown higher
resistance to fidaxomicin [122]. Thus, there is a need for better treatment strategies.
Piscidins are short antimicrobial host-defense peptides (HDPs) produced by the innate
immune systems of fish. These helical structured peptides have broad-spectrum antibacterial
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activities against most aerobic bacteria [58]. They also show strong antibacterial efficacy in
anaerobic conditions [123]. They can potentiate immune cells including lymphocytes and
monocytes by sensitizing the surface layer proteins (SLPs) of bacteria [59]. Due to their efficacy
against muti-drug resistance pathogens, novel therapies could be developed from HDPs.
Piscidins p1 and p3, derived from hybrid striped sea bass, can cause cell membrane disruption
and have DNA nuclease activity [62, 63]. These peptides have a very short, conserved Nterminal motif for metal binding called ATCUN, which binds some transition metals like copper
(Cu 2+) and nickel (Ni 2+) leading to increased efficacy in aerobic condition [124], but Cubinding does not enhance efficacy of either piscidins in anaerobic conditions [61].
The peptides accumulate in C. difficile at sites of membrane curvature and later cause cell
death [123]. Both piscidins are effective against the historical strain 630∆erm and the epidemic
R20291 strain that is highly resistant to antibiotics and other stressors [123]. Piscidins attack
different cellular targets than medical antibiotics, meaning that simultaneous treatments are not
likely to be redundant. We investigated the effect of piscidins on vegetative C. difficile survival
after antibiotic treatment and its effect on clostridial spore formation, as well as synergy between
the peptides and common antibiotics used for CDI treatment. We discovered that piscidin
treatment enhances antibiotic efficacy and prevents antibiotic-induced sporulation. Piscidins
reduced bacterial membrane integrity and increased uptake of exogenous substances, which
could increase uptake into bacterial cells.
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MATERIALS AND METHODS
Materials, Chemicals, Bacterial Strains and Growth Conditions
Materials and chemicals were purchased from Fisher Scientific (Hampton, NH, USA)
unless otherwise indicated. The bacterial strains used in this study are listed in Appendix D. C.
difficile 630∆erm and R20291 were maintained on brain-heart infusion supplemented with 5%
yeast extract (BHIS), agar plates [101, 102]. Where indicated, cells were treated with
ciprofloxacin, fidaxomicin, (Cayman Chemicals), erythromycin (Acros Organic), metronidazole
(BTC) or vancomycin (VWR). For spore enumeration, vegetative cells were killed by aerobic
incubation at room temperature with 50% ethanol for one hour and spores were germinated
anaerobically with 0.1% taurocholic acid (TCA from Sigma Life Science). Host defense peptides
(HDPs) piscidin 1 (p1), piscidin 3 (p3), and piscidin copper complexes were provided by
Myriam Cotten (College of William & Mary, Williamsburg, VA). All anaerobic bacterial culture
took place at 370C in a Coy anaerobic chamber (Coy Laboratory Products, Grass Lake, MI) with
an atmosphere of 85% N2, 10% CO2, 5% H2. All plastic consumables were equilibrated in the
anaerobic chamber for a minimum of 72 h.
Growth Inhibition Measurements
Saturated overnight cultures of C. difficile were inoculated dilution factor of the first
innoculation into fresh BHIS media and grown to log phase (OD600 + 0.4-0.6) and diluted 1:10
into fresh BHIS media in 200 µL sterile 96-well plates (Thermo Fisher Scientific) containing the
indicated concentration of peptides. Piscidins were either equilibrated for 3h in the anaerobic
chamber before adding or fresh peptides used immediately after import into the chamber. p1 and
p3 synergy were first tested with gradient concentrations from 0 to 32 µM and three independent
biologicals. The plates were maintained in the anaerobic incubator at 370C for 16h. After 16h,
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plate exteriors were removed from the anaerobic chamber and the exterior was sterilized before
the optical density was read at 630nm with a microplate reader (BioTek). Each experiment was
repeated three more times, mean and standard deviation reported.
Antibiotic Synergy Assay
The antibiotic synergy with piscidins and their copper complexes was measured at half of
the published inhibitory peptide concentrations [123]. Antibiotic gradients were designed to end
at 0.5x of the previously published inhibitory concentration each of the antibiotics [125-127].
The well-established antibiotics ciprofloxacin, erythromycin, fidaxomicin, metronidazole and
vancomycin were used at the indicated concentrations. Data represent the means and standard
deviations of three biologically independent samples.
Combinations of piscidins and drugs that restricted overnight C. difficile R20291 growth
to OD 600 ≤ 0.05 were assessed for viable cells by plating of the treated samples on BHIS. Cells
were exposed to synergistic combinations of antibiotics and piscidins as described above and
incubated for 16h before plating 100µL on BHIS plates with 20 µg/mL erythromycin. Plates
were incubated at 37oC for 48h before enumeration of colonies. Treated samples were compared
to untreated samples and to each other by two-way ANOVA using Tukey’s multiple comparison
test with Prism (GraphPad Software, San Diego, CA, USA). Data represent the means and
standard deviations of three biologically independent samples.
Live Cell Microcopy
Time-lapse, differential interference contrast (DIC) microscopic imaging of live C.
difficile R20291was bacteria performed on a Nikon Ti-E inverted microscope equipped with
apochromatic TIRF 60X oil immersion objective lens 4.2 LT sCMOS camera, and SOLA SE II
365 Light Engine as well as complementary DIC components (Nikon Instruments Inc, Melville,
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NY, USA). Exponentially growing (OD600 = 0.5 - 0.6) cells were mixed with peptides (p1 and p3
at 0.5x the inhibitory concentration), peptide-metal complexes (p1Cu and p3Cu at 0.5x the
inhibitory concentration) or 4.00 µM CuSO4, FeSO4, MgSO4 and AgNO3. and phosphate-buffer
saline (PBS) was added inside the anaerobic chamber to a final volume of 1.5 mL.
The samples were injected into mobile anaerobic rose-type imaging chambers as
previously described by Courson et al 2019 [104]. The airtight imaging chamber was removed
from the anaerobic chamber, the exterior sterilized, and placed on the microscope with an
average time lapse of ten minutes. The microscope was maintained at 37 0C using a home-built
enclosure and a Nevtek Air Stream microscope stage warmer (Nevtek, Williamsville, VA, USA).
Nikon Perfect Focus system was employed to eliminate focal drift during recordings. Cells were
recorded for 24h, with three randomly selected fields of view image every 30 minutes. Data
analyses were performed using the Nikon Elements imaging suite ImageJ image tools. During
imaging analysis spores, pre-spores (or mother cells), and vegetative cells were quantitated.
Piscidin Uptake Assays
4 mL samples of C. difficile cultures in late exponential growth (OD600 0.7-0.8) were coincubated anaerobically at 37°C with 20 µg/mL propidium iodide (PI) (Biotium), and inhibitory
concentrations of piscidins or piscidin-copper complexes (4 µM for p1 and p1Cu, 8 µM for p3
and p3Cu) [123]. Samples containing apo-peptides were incubated for 30 minutes and samples
containing metalated peptides were incubated for 10 minutes. After incubation, cells were
centrifuged for 5 minutes and resuspended in 1.5 mL fresh BHIS. Negative controls were
incubated with PI for 10 or 30 minutes, with no peptide and then centrifuged at 3000rpm for 5
minutes and resuspended. Positive control samples were exposed to oxygen for 1h and incubated
aerobically at room temperature with propidium iodide and 50% ethanol. Samples were injected
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into rose chambers for microscopic imaging as detailed in Courson et al 2019 [104]. The rose
chambers were removed from the anaerobic chamber and the outsides were sterilized with 70%
ethanol and 10% bleach. Nikon Perfect Focus system was employed to eliminate focal drift
during recordings.[128]. The PI fluorescence was measured using 553/650 nm
excitation/emission filters.
Spore Enumeration Assay
BHIS liquid media and BHIS agar plates containing 20µg/mL erythromycin alone or
20µg/mL erythromycin + 0.1% taurocholic acid (TCA) (Cayman Chemicals) were equilibrated
in the anaerobic chamber overnight. 4mL of fresh liquid media was inoculated 1:10 with a
saturated overnight culture. The inoculated culture was allowed to grow anaerobically for 4h at
37 0C until late log-phase (OD600 0.8 to 0.9) [129], and then, treated with 0.5x inhibitory
concentration of piscidins, peptide-metal complexes, CuSO4 or antibiotics respectively [123,
125, 126]. 0.5 mL each of the samples were removed from the anaerobic chamber at the
indicated time points, with one untreated control removed to aerobic conditions and one left
anaerobic. Samples was exposed to oxygen for 1h and ethanol were added to a final
concentration of 50%. All samples were serially diluted and plated in duplicate on BHIS
containing 20µg/mL erythromycin and 0 or 0.1% TCA [130]. Plates were incubated
anaerobically for 48h at 370C before colony enumeration. Treatments were repeated on a
minimum of three biologically independent samples. For antibiotic-piscidin synergy
experiments, samples were exposed to the combined treatments for 16h before dilution and
plating.
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RESULTS
Piscidins Are Most Effective When Equilibrated to Their Oxygen Environment
We determined that the piscidins must be equilibrated to the anaerobic environment to
yield consistent results. The efficacy of 2.00µM p1 and p3 4.00µM p3 at killing C. difficile was
measured using peptides either equilibrated in the anaerobic chamber for 3h before use or
immediately upon bringing them into the chamber, still contaminated with environmental
oxygen. The equilibrated peptides were more effective at inhibiting anaerobic C. difficile growth,
keeping the OD630 after 16h at 0.0 at 2.00 µM (p1) or 4.00 µM (p3) compared to 4.00 µM (p1)
and 8.00 µM (p3), for the unequilibrated peptides. The unequilibrated numbers were consistent
with those reported in Oludiran et al 2019 after 16h incubation (Figure 15a). The equilibrated
piscidins act additively, as both peptides inhibit the C. difficile growth at lower concentration
compared to either piscidins alone (Figure 15b).
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Figure 15: Piscidins strongly inhibit the C. difficile growth anaerobically and they act
additively (a) When p1 and p3 are combined at 0.25x their respective MICs the combined
treatment (gold) is more effective than p3 alone (green) at 0.5x MIC. Similar results were
obtained with p1 (data not shown) (b) p1 equilibrated to the anaerobic environment for 3h
before application (blue triangles) inhibited C. difficile growth at a lower concentration than
p1 applied immediately after import into the anaerobic chamber while it was still
contaminated with oxygen (blue squares). The same result was found for anaerobic p3 (green
diamonds) and oxygen-contaminated p3 (green triangles). The data shown are the means and
standard deviation of six biologically independent samples.
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Piscidins Synergize With Antibiotics to Strongly Inhibit Proliferating C. difficile Cells
The ability of piscidins to synergize with antibiotics was tested with three clinically
relevant antibiotics commonly used for the treatment of CDI [34]; fidaxomicin (FID),
metronidazole (MET) and vancomycin (VAN). Ciprofloxacin (Cipro), to which C. difficile is
resistant, was used as a control [131]. Varying concentration of antibiotics were combined with
constant concentration of apo or metalated peptides at 0.5x inhibitory concentrations. Both FID
and MET inhibited growth at lower concentrations in the presence of piscidins (Figure 16-19).
The MICs of FID, MET, and VAN alone were 0.5 µg/mL, 4 µg/mL, and 4 µg/mL, respectively.
The presence of p1, p1Cu, p3, or p3Cu at 0.5x inhibitory concentrations increases the efficacy of
all the functioning antibiotics far below their published in vitro minimum inhibitory
concentrations (MICs) as summarized in Table 2 and Figures 16-19 ([125, 126].

Table 2. Co-treatment with antibiotics-piscidins combinations reduces C. difficile growth.
Antibiotic

No peptide

2µM p1

2µM p1Cu

4µM p3

4µM p3Cu

Metronidazole

>4

1

1

2

0.5

2 µM p1
4 µM p3
0.25

Vancomycin

4

2

0.5

0.5

0.25

0.25

Fidaxomicin

0.25

0.1

0.05

0.05

>0.1

0.0125

Ciprofloxacin

>128

n/a

n/a

n/a

n/a

n/a
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Figures 16. C. difficile growth in the presence of FID and 0.5x inhibitory levels of piscidins.
Overnight growth was monitored at 630nm in the presence of the indicated concentration of
fidaxomicin and subinhibitory levels of p1 alone (a), p1 with copper (b), p3 alone (c), or p3
with copper (d). Shown are the means and standard errors of at least three biologically
independent samples.
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Figures 17. C. difficile growth in the presence of MET and 0.5x inhibitory levels of piscidins.
Overnight growth was monitored at 630nm in the presence of the indicated concentration of
fidaxomicin and subinhibitory levels of p1 alone (a), p1 with copper (b), p3 alone (c), or p3 with
copper (d). Shown are the means and standard errors of at least three biologically independent
samples.
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Figures 18. C. difficile growth in the presence of VAN and 0.5x inhibitory levels of piscidins.
Overnight growth was monitored at 630nm in the presence of the indicated concentration of
fidaxomicin and subinhibitory levels of p1 alone (a), p1 with copper (b), p3 alone (c), or p3 with
copper (d). Shown are the means and standard errors of at least three biologically independent
samples.
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Figures 19. C. difficile growth in the presence of Cipro and 0.5x inhibitory levels of piscidins.
Overnight growth was monitored at 630nm in the presence of the indicated concentration of
fidaxomicin and subinhibitory levels of p1 alone (a), p1 with copper (b), p3 alone (c), or p3 with
copper (d). Shown are the means and standard errors of at least three biologically independent
samples.

Peptide-Antibiotic Synergy Against Viable Cells
We needed to determine whether the piscidin-antibiotic combinations that kept bacterial
culture density below OD630 ≤ 0.05 were killing bacteria or merely suppressing bacterial growth.
We diluted samples treated with these combinations and plated them to count viable colonies.
We found that co-treated samples containing FID or MET had at least 90% fewer live cells than
untreated controls (Figure 20a, b). Combined treatments containing VAN reduced the number of
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cells by 50-90% (Figure 20c). The combination of piscidin and the ineffective antibiotic Cipro
did not kill bacteria, showing that the piscidins were enhancing the antibiotics but were not
sufficient to kill the bacteria in the absence of an effective antibiotic at the tested concentrations
(Figure 20d). Copper appeared to increase the p1 and p3 synergy with FID (Figure 20a) and p1
synergy with MET (Figure 20b) but had no effect on the synergy with VAN (Figure 20c) or
Cipro (Figure 20d). The cell counts of samples treated with FID or MET in combination with
piscidin-metal complexes were at least 90% fewer than untreated controls.
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Figure 20. Piscidins lower the effective MICs of antibiotics and reduce viable cell numbers.
Colony-forming units per mL of C. difficile cells after treatment with piscidins and fidaxomicin
(a), metronidazole (b), vancomycin (c), or ciprofloxacin (d). CFU counts were compared to
those in untreated controls by two-way ANOVA with Tukey’s post-test comparison and using at
least three independent biologicals. nt, not treated; n.s., not significant; * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001. Shown are the means and standard errors of at least three
biologically independent samples.

We used microscopy to investigate a possible mechanism for the increased efficacy of
antibiotics in the presence of piscidin. The peptides are known for directly killing bacteria
aerobically by either causing DNA damage or membrane disruption, so we speculate that
membrane disruption could allow antibiotics to penetrate the cytoplasm. We employed
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propidium iodide as a fluorescent trace to verify the idea that membrane disruption allowed
external substances to move freely into the cells. PI is excluded from cells with intact
membranes. The number of cells with red staining is very sparse in the untreated, undamaged
negative control (Figure 21). Oxygen and ethanol triggered extensive PI uptake, as expected
(Figure 21). PI staining was extremely high in cells treated with both piscidins and their copper
complexes (Figure 21). This confirmed the ability of the piscidins and their copper complexes to
cause membrane disruption that could enhance antibiotic uptake and efficacy.

a

c

e

b

d

f

Figure 21. Piscidins allow increased propidium iodide uptake (a) Negative control with PI but no
oxygen and no other treatment. (b) Positive control with PI, oxygen, and 50% ethanol treatment.
(c) PI and p1 alone were co-treated, with no oxygen. (d) PI and p3 alone were co-treated with no
oxygen. (e) PI and p1Cu treatment but no oxygen. (f) PI and p3Cu co-treatment without oxygen.
The scale bar represents 10 microns
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Exposure to Antimicrobial Peptides and Metals Affects C. difficile Morphology
C. difficile R20291 was imaged on an inverted microscope at 60x magnification at 30minute intervals after treatment with piscidins or with transition metals known to induce
oxidative stress. The bacterial morphology varies according to the source of the induced stress.
The images show that sub-inhibitory 4.00 µM concentration of non-antimicrobial metals of +2
oxidation states Fe, Mn, and Mg, enabled robust continuous cell growth and stimulated only
moderate spore formation (Figure 22), while piscidins and their piscidins copper complexes
appeared to have both fewer numbers of C. difficile vegetative cells and spores (Figure 23) .
However, the known antimicrobial metals Ag and Cu increased the number of spores visible by
bright-field microscopy (Figure 24).
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Figure 22. Non-antimicrobial metal treatment does not affect C. difficile morphology. Cells
treated with 4 µM of Cu2+, Fe2+, Mg2+, and an untreated control are shown 0, 4h, and 24h
after exposure. Scale bars in all images represent 10 microns. Selected vegetative cells are
marked with blue arrows and selected spores are marked with red arrows.
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Figure 23. Piscidin treatment appeared to reduce C. difficile cells. Cells treated with 0.5x of p,
p1Cu, p3, p3Cu, and a 1XPBS treated control are shown at 0, 12h, and 24h. Scale bars in all
images represent 10 microns. Selected vegetative cells are marked with blue arrows and
selected spores are marked with red arrows.
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Figure 24. Metal treatment affects C. difficile morphology. Treatment with 4 µM Cu2+, cause
cells to sediment on the bottom surface of the imaging chamber in a nest-like morphology after
2h continuing through 24h. The same morphological changes were seen when treated with an
Ag+ (image not shown). Scale bars in all images represent 10 microns

Piscidins and Piscidin-Copper Complexes Do Not Induce Sporulation in C. difficile
To confirm the visual observation that samples treated with piscidin had fewer spores we
subjected treated samples to oxygen and ethanol to kill off any surviving vegetative cells and
then germinated the spores to count them. Both piscidin and piscidin-copper complexes caused a
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significant reduction in the numbers of spores over time at their 0.5x inhibitory concentrations of
2.00µM (p1&p1Cu) and 4.00µM (p3&p3Cu). The cells exposed to 0.5x inhibitory
concentrations of both peptides and their complexes had no significant differences from the
untreated controls at the beginning of the experiment. After 3h, the number of spores in the
untreated control increased significantly and the number of spores in the treated samples was
constant or diminished. p1 and p1Cu induced a threefold reduction in the number of spores
compared to the untreated negative control (Figure 25a). In p3 and p3Cu there was twofold
reduction in the number of spores (Figure 25b). Copper ions made no appreciable difference in
the effect of p1 on sporulation, and copper-bound p3 appeared to suppress sporulation even more
than p3 alone.
Copper Alone Induces Sporulation in C. difficile
We have previously reported that copper alone is inhibitory against C. difficile
presumably by causing oxidative stress. Exposure to sub-inhibitory copper sulfate increases
spore formation after 3h (Figure 25 c), even though copper complexed to p1 and p3 did not have
this effect (Figure 25 a, b).
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Figure 25. Piscidins do not stimulate sporulation, but copper does. (a) p1 and p1Cu decrease the
formation of viable spores after 3h of treatment compared to non-treated controls (b) p3 and
p3Cu reduce the number of germinating spores immediately and after 3h of treatment plots (c)
Treatment with copper sulfate stimulate the formation of more spores in 3h than in the
nontreated control. Using two-way ANOVA with Tukey’s post-test comparison. nt, not treated;
n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Shown are the
means and standard errors of at least three biologically independent samples.

Piscidin-Antibiotic Combinations Do Not Trigger Sporulation
Samples treated with piscidins, and piscidin-copper complexes showed reduced
sporulation even though copper alone increased spores (Figure 25c). While fidaxomicin reduced
expression of C. difficile sporulation gene and inhibits sporulation in vitro, metronidazole and
vancomycin have been reported to not affect sporulation or to mildly stimulate sporulation in
some straw and clindamycin [48, 132-134].. We evaluated the effect of 0.5x of inhibitory
concentrations of p1 and p3 administered in the presence of fidaxomicin, metronidazole or
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vancomycin. C. difficile sporulation was reduced in the presence of these combinations (Figure
26 a, b, and c). p1 alone and p3Cu appeared to suppress spores in the presence of the ineffective
antibiotic Cipro, but the result was not statistically significant (Figure 26d).
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Figure 26. Spore enumeration after treatment with piscidins and antibiotics (a) Fidaxomicin in
combination with piscidins and their copper complexes reduced C. difficile sporulation (b)
Metronidazole in combination with piscidins and their copper complexes reduced C. difficile
sporulation (c) Vancomycin in combination with piscidins and their copper complexes slightly
reduced sporulation in the case of p1 and p3Cu (d) Ciprofloxacin in combination with piscidins
and their copper complexes sporulation not reduced. Data were analyzed using two-way
ANOVA with Tukey’s post-test comparison. nt, not treated; n.s., not significant; * p < 0.05; ** p
< 0.01; *** p < 0.001; **** p < 0.0001. Shown are the means and standard errors of at least
three biologically independent samples.
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DISCUSSION
p1 and p3 act additively in an anaerobic environment against C. difficile. The two
peptides were able to inhibit bacterial proliferation at a lower concentration of both in
comparison to each peptide acting alone. Oxygen-contaminated peptides applied immediately
after being brought into the anaerobic chamber supported the level of efficacy established by
Oludiran et al 2019, but peptides equilibrated for 3h in anaerobic chamber before usage are more
efficient. We speculate that trace oxygen activates the bacterial oxidative response pathways,
which incidentally increases the resistance to piscidin. In addition to synergizing with each other,
sub-inhibitory amounts of piscidins increase the efficacy of antibiotics used in the treatment of
CDI.
The ability of the peptides to increase uptake of exogenous propidium iodide in living
cells suggested that the peptides may permeabilize the cell membrane, increasing uptake of
antibiotics and making it easier for antibiotics to access their intracellular targets. While copper
does not enhance the anaerobic antimicrobial activity of p1 or p3 alone, metalated peptides were
more effective than peptides alone at stimulating PI uptake or synergizing with antibiotics. This
may be because copper stabilizes peptide interactions with the membrane to increase
permeability has been suggested by studies monitoring fluorescent dye entry into non-living lipid
vesicles [135]. DIC microscopy suggested an increase in sporulation in the presence of
antimicrobial metals that cause oxidative stress, which was confirmed by spore germination and
quantification assays. Interestingly, treatment with 4µM Cu (II) salts also affect vegetative cell
morphology. The treated cell showed a nest-like new arrangement not seen before they settled
out of the solution. This aggregation could be a precursor to biofilm formation to try to
collectively reduce the effect of oxidative stress.
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The discovery that oxidative stress from metal ions induces sporulation in C. difficile
suggested that the loss of vegetative growth observed after piscidin treatment could be partly due
to cells differentiating into spores instead of reproducing. However, all the metalated and nonmetalated peptides reduced spore formation in direct comparison with the untreated samples,
showing that piscidins kill vegetative C. difficile without triggering sporulation. Interestingly,
copper alone stimulates sporulation but not if the piscidins are present, suggesting that the
peptides suppress sporulation. However, piscidins can be used to boost antibiotic treatments
without triggering increased C. difficile sporulation, and no cell will be able evade antibiotic
treatment.
Summary
These antimicrobial peptides and their copper complexes give a helping hand to the
effective antibiotics fidaxomicin, metronidazole, and vancomycin by lowering their needed
dosage and increasing their efficacy against vegetative C. difficile. This effect does not extend to
non-functioning antibiotics like ciprofloxacin, showing that both partners need to be functional
to synergize. Peptides alone or with their copper complexes can suppress sporulation in C.
difficile, even in the presence of antibiotics that induce stress needed to stop bacterial cell
proliferation.
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CHAPTER IV
BIOFILM PRODUCTION AS PHENOTYPIC RESPONSE TO ENVIRONMENTAL AND
IMMUNE STRESS IN C. DIFFICILE
OVERVIEW
Biofilms are the aggregation of microbes of one or many species embedded within a
matrix in surface-attached communities that secrete biofilm-specific extracellular products.
While anaerobic biofilms impact health, industry, and the environment, biofilms are mostly
studied in vitro in the presence of oxygen because of the difficulty of growing and analyzing
them anaerobically [10, 135]. C. difficile can form biofilms as a single species or with other
anaerobic intestinal bacteria on different biotic and abiotic surfaces, which helps them survive
antibiotics and other stresses [136]. C. difficile strains that form strong biofilms in vitro are more
likely to cause recurrent CDI [137]. In recent years, the potential contribution of biofilms to C.
difficile pathogenesis has been a strong subject of interest especially their part in CDI recurrence.
The role of stresses that induce or disrupt biofilm in the intestinal microbiota is not well
understood and there is little information on C. difficile colonization of the gastrointestinal tract.
Environmental and physiological stresses can stimulate biofilm formation response in
other bacterial species [138]. Some harsh environmental conditions can lead microorganisms to
accumulate reactive oxygen species (ROS), which produce or mimic intracellular oxidative
stress. Oxidative stress acts as a cue, triggering bacteria to activate effective oxygen scavenging
mechanisms or to shift metabolic pathways. Oxidative stress responses which are shared among
most bacteria include gene expression induced by conserved regulators, production of
extracellular polymeric substances, and biofilm formation. Mitigation of C. difficile biofilm
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production could be helpful to control the virulence and infection recurrence of this organism
[138].
The biofilm matrix can include polysaccharides, proteins, and nucleic acids, together
called extracellular polymeric substances (EPS); the exact nature of the biofilm matrix depends
on the identity of the bacteria within it [53, 54]. The biofilm structure and /or architecture dictate
the ability to attach either to biotic or abiotic surfaces and survive stress. Biofilm composition,
compactness and amount also vary according to the available nutrients in the environment [139].
The three-dimensional structure of biofilms give insight into their attachment ability to different
surfaces and antibiotics resistance capacity of cells in the biofilm. Biofilms with more
polysaccharide composition with moderate extracellular nucleic materials and proteins tend to
form clumped aggregates and are less resistant to external stresses. Biofilms with higher
proportions of nuclear material and protein form three-dimensional carpet-like aggregates which
protect the component cells and improve stress survival [56]. Previous studies have shown that
deoxycholate or pyruvate induced C. difficile to form surface adherent biofilms in 48h. We
investigate environmental stressors like antibiotics, antimicrobial metals, antimicrobial peptides,
and oxidants (diamide and tert-butyl hydroperoxide tBHP) applied in vitro to mimic the in vivo
environment of the bacteria during infection and quantify stress-induced C. difficile biofilm
formation.
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MATERIALS AND METHODS
Materials, Chemicals, Bacterial Strains and Growth Conditions
Materials and chemicals were purchased from Fisher Scientific (Hampton, NH, USA)
unless otherwise indicated. The bacterial strains used in this study are listed in Appendix D. C.
difficile 630∆erm and R20291 were maintained on brain-heart infusion supplemented with 5%
yeast extract (BHIS) agar plates [101, 102]. Biofilms were grown in untreated 24 well plates in
BHIS media supplemented with 1% glucose and 50mM Na2PO3 (pH = 7.4). Where indicated,
cells were treated with CuSO4, AgNO3, MgSO4, diamide, (MP Biomedicals) or tert-Butyl
hydroperoxide (tBHP) to induce oxidative stress. Host defense peptides (HDPs) piscidin-1 (p1),
piscidin-3 (p3), and piscidin copper complexes were provided by Myriam Cotten’s lab (College
of William & Mary, Williamsburg, VA). All anaerobic bacterial culture took place at 370C in a
Coy anaerobic chamber (Coy Laboratory Products, Grass Lake, MI) with an atmosphere of 85%
N2, 10% CO2, 5% H2. All plastic consumables were equilibrated in the anaerobic chamber for a
minimum of 72 h [140, 141].
C. difficile Biofilm Growth and Quantification
Four biologically independent cultures of R20291 were used to inoculate 2.00mL/well of
BHIS media with supplemented 1% glucose and 50 mM Na2PO3 (Fisher Scientific) at pH 7.4
(Mettler-Toledo), using 200µL of log phase culture in sterile equilibrated 24-well plates. Culture
was incubated for 2 hours before treatment with the indicated concentrations of respective
treatments at sub-lethal concentrations and incubated anaerobically at 370C for 48h. After the
48h of growth, cell density was measured at 630/nm. Non-adhered planktonic cells were
removed by pipetting and wells were washed with 1 mL 1x phosphate buffered saline solution
(1xPBS), stained for 30 minutes with 0.1% crystal violet, and then washed twice with 1 mL each
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of 1xPBS. The adhered stain was suspended in 70% ethanol before scanning the plate at 570/nm,
using the Bio-Tek plate reader [61].

RESULTS
Piscidins and/or their copper complexes showed significant stimulation of C. difficile
biofilm production. Gradient concentrations of piscidin and piscidin-copper complexes from 0.0
to 2.0 µM, showed that apo- and metalated peptides increase the amount of biofilm produced. At
1µ M p1 there is a two-fold increase in the amount of biofilm produced and this continued up to
2µM concentration point. The same response was seen with p1Cu (Figure 17a). Biofilm
production was also increased by both p3 and the p3Cu complex, with the p3Cu complex having
a more pronounced effect (Figure 17b).
Transition metals are known to be antimicrobial, with a presumed mechanism of action
involving serving as a source of oxidative stress antimicrobial metals. We have shown that
copper kills C. difficile and inhibit its growth (Chapter II Figure 6) [123]. Here we have shown
that silver is also antimicrobial at millimolar concentrations (Figure 26). A similar level of
magnesium is not antimicrobial, showing that the observed effect of the transition metals is not
osmotic (Figure 26). The antimicrobial metals of have a dose-dependent effect on biofilm.
AgNO3 showed significant increase in biofilm production at 4µM (Figure 25d), and the same
response is seen in CuSO4 at 32µM (Figure 25c). We compared antimicrobial metals (Ag & Cu)
and non-antimicrobial metal (Mg). We found a significant difference in biofilm formation for
both concentration gradient of Ag (2 µM and 4 µM) and a strong trend but no significant
differences for Cu for the tested concentrations while Mg does not cause any observable changes
(Figure 25). In the case of oxidative stress inducers (diamide and tert-Butyl hydroperoxide
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tBHP) which mimic environmental conditions in vitro, we show that biofilm production response
by the bacteria is selective. There was a twofold increase for biofilm produced in the presence of
diamide but no significant difference in the biofilm produced by tBHP at gradient concentrations
of both oxidants in treated media and cell culture (Figure 25). There was a twofold increase in
the amount of biofilm produced in the presence of diamide but no significant difference in
biofilm produced after treatment with tBHP.
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Figure 27. C. difficile biofilm production in response to different inducers (a) Biofilm produced
after treatment with p1 and p1Cu (b) Biofilm produced after treatment with p3 and p3Cu (c and
d) Biofilm produced with the treatment of antimicrobial metals (e) Biofilm produced after
treatment with antimicrobial metals (Ag and Cu) and a non-antimicrobial metal (Mg). (f)
Graphical representation of biofilm produced after treatment with the oxidative stressor diamide
(g) Biofilm produced after treatment with the oxidative stressor tBHP. Treated conditions were
compared to untreated conditions by using two-way ANOVA with Tukey’s post-test
comparison. nt, not treated; n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p <
0.0001. Shown are the means and standard errors of at least three biologically independent
samples.
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DISCUSSION
C. difficile biofilm formation in response to oxidative stress varies depending on the
source of the stress. p1 and p1Cu are major biofilm inducers at their published 0.5x inhibitory
concentrations and showed dose dependance as the concentrations increased. The effect was less
pronounced with p3 and was only significant in the presence of copper. P1, p3 and their copper
complexes cause membrane disruption which might sensitize the activation of surface defense
mechanism of the bacteria to quickly secrete extracellular matrix so as to protect themselves
from extracellular attack. Metal bioavailability also influences the bacterial cells. Disturbance to
metal homeostasis in the GI tract can lead to diverse types of response by different bacteria in
that habitat. Many vertebrates maintain a consistent amount of metals in their GI tract to not only
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promote enzymatic activities (by acting as cofactors), but to also prevent proliferation of
bacterial cells, for which metals can be growth-limiting nutrients but which can suffer redox
damage in the presence of excessive metal [142]. Ag and Cu used in medical tools are believed
to prevent bacterial growth, but they have never been evaluated for the prevention of biofilm
formation [143].
Supplementation with non-transition metal salts did not stimulate biofilm formation,
indicating that biofilm is formed as a result of oxidative stress induced by the antimicrobial
metals at the indicated concentrations. Antimicrobial peptides and metals are not the only
sources of oxidative stress but the fact that they have the same effect on biofilm formation
suggests that it is a general response to oxidative stress. We employ diamide and tBHP as both
are organic oxidant; they are used as sources of oxidative stress because they do not break down
as easily as hydrogen peroxide in an anaerobic condition. These organic oxidants use two
different mechanisms in exacting oxidative stress. Diamide induce disulfide bond breakage,
while tBHP accelerate the oxidation of glutathione, and both are subcategories of oxidative
stress. Only diamide at sub-inhibitory concentrations stimulated more biofilm formation in vitro
against C. difficile while tBHP does not, which suggests that biofilm induction in response to
oxidants could be source dependent. So, in all indication, exposure to sub-lethal oxidative stress
induces biofilm formation as a survival mechanism.
Summary
The production of biofilms shield bacterial communities from extracellular stress and increases
bacterial survival. While piscidins are effective killers of the C. difficile, sublethal concentrations
do stimulate biofilm formation. This could complicate the use of piscidins as treatments for CDI
in vivo.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
Stress survival by the pathogen C. difficile contributes to the infection’s spreading to new
host via spore formation as well as vegetative cell survival within one host. In this dissertation
we investigate the phenotypic stress responses of C. difficile. Sporulation and biofilm formation
are both important morphological responses to different stresses. More information about these
processes is very necessary to design new treatments to combat the pathogenicity of this multidrug resistant bacterium, wreaking havoc in both industrialized nations and developing countries.
Since the beginning of the 21st century CDI is not slowing down in infection spreading. So
strong alternative treatments for the pathogen are urgently needed.
We propose a new strategy, the usage of AMPs (specifically piscidins). In chapter II of
this dissertation, we applied piscidins to an anaerobic pathogen for the first time and found that
they are a viable strategy to attack anaerobic bacteria. We investigated the response of the
pathogen to environmental and immune stresses in terms of the vegetative cell viability, spore
production and biofilm formation. The importance of the phenotypic expression of spore and
biofilm for this bacterium cannot be over-stressed because of their contribution to infection
spread and resistance to most classes of antibiotics. Piscidins and their copper complexes inhibit
the growth of C. difficile in anaerobic conditions. The peptides and their metalated complexes
were able to significantly reduce the population of already existing C. difficile cells in the same
anaerobic condition. Aerobically, it was reported that addition of copper metal to the piscidin
significantly increases their efficacy, but this is not the same in anaerobic condition. Copper on
its own can inhibit bacterial proliferation but does not enhance piscidin lethality anaerobically.
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We established that piscidins can associate with the membranes of the bacterial cells, which
positions them to impair membrane integrity [123].
In chapter III of this dissertation, we showed that the piscidins’ antimicrobial activities
are stronger when residual oxygen has been removed and prevented from activating antioxidant
stress responses, suggesting that piscidins induce oxidative stress in this organism. We also
showed that the piscidins evaluated can synergize with each other and with clinically relevant
antibiotics. Piscidins strengthen antibiotics by lowering their dosage and increasing their efficacy
against the anaerobic pathogen. This complimentary effect could help improve the potency of
CDI treatment antibiotics that are already lost or are losing their efficacy. The cooperation effect
between antibiotics and sublethal amount of piscidins are not extended to non-functioning
antibiotics, proving that the peptides boost the antibiotics even when they are not present at high
enough level to be lethal themselves, the peptide at the supplied concentrations will not be able
to provide effective killing unless they synergize with functioning antibiotics. The propidium
iodide uptake experiments suggest that the piscidins boost the antibiotic efficacy by increasing
antibiotic uptake into the cells.
The most exciting finding is that the synergy between piscidins and antibiotics leads to
sporulation suppression in C. difficile. C. difficile sporulation stage was reported to be the major
bacteria life cycles stage that many of the antibiotics do not have direct inhibitory or suppression
effect on except fidaxomicin. Presence of piscidins, with those functioning antibiotics at their
sub-inhibitory concentrations, simultaneously carryout their antibacterial activities and
sporulation suppressions. So, functioning antibiotics worked in synergy with the peptides and
peptides-metal complex. Earlier investigation already established that piscidins can stand alone
in killing off the vegetative cells of C. difficile and now our new findings confirmed that they can
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work in cooperation with other antibiotics to conduct the antimicrobial effect. Treatment that
attacks vegetative C. difficile without triggering sporulation are highly sought after to combat
CDI and piscidin show exciting potential for this.
Our investigation in chapter IV of this dissertation reveals that biofilm formation is a
stress survival strategy activated separately from sporulation in C. difficile. Biofilm formation is
another phenotypic expression to survive extracellular stress. Piscidins, reported to induce
unique form of stress by causing both cell membrane disruption and DNA damage, can also
induce the bacterial cells to produce biofilm at sub-inhibitory concentration. Other environmental
stressors, including antimicrobial metals, can also stimulate biofilm formation. The nonoxidative stress agent diamide, which breaks disulfide bonds, also induces biofilm formation,
while tBHP, an organic oxidant that induces oxidative stress by causing an increase in ROS, does
not influence the amount of biofilm produced by C. difficile. This shows that stress induced
biofilm formation in this organism is specific to different stress sources. This could limit
piscidins’ usefulness as a treatment against C. difficile because sub-inhibitory concentration of
these peptides might encourage biofilm formation and bacterial resilience. Future work will
evaluate whether combinations of peptides and antibiotics exhibit cooperation against C. difficile
biofilm and whether they disrupt already formed biofilm in anaerobic conditions as these have
been reported to do aerobically. Bacteria live up to the saying “what does not kill you makes you
stronger.” So, when these peptides are coupled into therapies it is not only the oxygen level of
the target sites that should be considered, but the lethality dosage threshold is also particularly
important to avoid triggering biofilm formation.
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APPENDIX A
INHIBITORY CONCENTRATION DETERMINATION
MIC-tBHP
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Inhibitory concentration determination. C. difficile R20291 cell density after overnight growth in
BHIS medium having the indicated concentrations of the treatments. Log phase cells of R20291
were inoculated at 1:10 into fresh BHIS media treated with gradient concentrations. Cells were
incubated anaerobically at 37°C to check cells’ turbidity at 630nm. (a) tBHP inhibitory
concentrations (b) NaCl inhibition concentrations and (c) Nisin inhibitory concentration
determination. Shown are the means and standard deviations of at least three biologically
independent samples.
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APPENDIX B
DIAMIDE INHIBITORY CONCENTRATION DETERMINATION

[mM]
Diamide inhibitory concentration determination. Log phase cells of R20291 were inoculated at
1:10 into fresh BHIS media treated with gradient concentrations of diamide and samples were
incubated anaerobically at 37°C to check turbidity at 630nm. Shown are the means and standard
deviations of at least three biologically independent samples.
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APPENDIX C
C. DIFFICILE SPORES AT 0.5x ANTIBIOTIC CONCENTRATIONS

a

Spore CFU/mL After 0.5x VAN or MET
****
***

Spore CFU×103/mL

200

NT+O2 TCA
VAN (0.5X)

150

MET (0.5X)
100
50
0

0

b

3
6
Time (hrs)

Spore CFU/mL For FID
**

50
CFU 103/mL

12

NT+O2 TCA

40

FID (0.5X)

30
20
10
0
0

3
6
Time (hrs)

12

C. difficile spores at 0.5x antibiotic concentrations. Late log phase cells of R20291 were
inoculated with antibiotics at one-half lethal dosages. (a) shows the plot of MET and VAN spore
count against time (b) FID spore count against time. Samples were treated aerobically at room
temperature with ethanol to make 50% the sample volume and left for 1h with occasional mixing
in order to kill all vegetative C. difficile before plating on 0.1%TCA+ 20µg/mL erythromycin
plates and incubated anaerobically at 37°C.
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APPENDIX D
C. DIFFICILE STRAINS USED IN THIS WORK
Clostridioides difficile
630Δerm

Derivative of strain 630 lacking the
erythromycin resistance gene ermB

R20291

Epidemic strain
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APPENDIX E
C. DIFFICILE GROWTH IN THE PRESENCE OF METAL

C. difficile growth in the presence of metals. R20291 growth for in the presence of the indicated
concentrations of metal. Log phase cells of R20291 were inoculated at 1:10 into fresh BHIS
media treated with indicted concentration metals. Cells were incubated anaerobically at 37°C to
check cells’ turbidity every 1hr before and after mixing. (a) OD at 600nm unvortex samples and
(b) is the OD 600nm vortex samples. Shown are the means and standard deviations of at least
three biologically independent samples [45].
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APPENDIX F
MODIFICATION OF PRIMARY BILE ACIDS

Modification of primary bile acids. The schematic diagram illustrate the conversion of bile acids
from the primary state to secondary form in the GI tract making use of enterohepatic circulation
[45].
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